{"id":"W2088460013","doi":"10.1007/s10637-014-0082-9","title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":189,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Rash; Internal medicine; Cancer; Adverse effect; Pharmacodynamics; Breast cancer; Oncology; Tolerability; Phases of clinical research; Colorectal cancer; Clinical trial; Gastroenterology; Pharmacokinetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162879,0.001604494,0.002326386,0.0006332422,0.000450822,0.001101927,0.001056519,0.001144086,0.002907024],"category_scores_gemma":[0.0007330725,0.0006917366,0.001275788,0.0006729442,0.0009802679,0.001089884,0.0004857002,0.005112633,0.000854585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001305185,"about_ca_system_score_gemma":0.001504055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00132167,"about_ca_topic_score_gemma":0.003334597,"domain_scores_codex":[0.9995914,0.0001465165,0.0000158356,0.00007012729,0.00004465229,0.0001314561],"domain_scores_gemma":[0.9995086,0.00005851236,0.00007880715,0.00005478745,0.00002524843,0.000274115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.529977,0.1492973,0.006658042,0.0008987432,0.001850319,0.0002909274,0.0005784447,0.01051455,0.07651227,0.0008630699,0.01331217,0.2092472],"study_design_scores_gemma":[0.5606875,0.4068362,0.01550708,0.00003700909,0.000508476,0.0003848098,0.0001206187,0.004111188,0.006995921,0.0005951358,0.004155405,0.00006081284],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990767,0.002080883,0.0007062385,0.0007555885,0.0001604865,0.001816014,0.001189008,0.0002035529,0.002321225],"genre_scores_gemma":[0.9886308,0.001554365,0.001715258,0.0009352974,0.0000977053,0.002076504,0.002379034,0.00005603439,0.002555085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002907024,"threshold_uncertainty_score":0.009725034,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009291892874384198,"score_gpt":0.2711400666733916,"score_spread":0.2618481737990074,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}